4th Future of Health Asia
November 19th 2024 | Singapore
Showcasing success stories and evidence-based outcomes of health innovation, take your place among 500 health leaders and gain actionable strategies to implement within your organisation.
Together let's dive into the cutting-edge of healthcare innovation
Join the waitlist
Vice-minister for health, and chief medical and global health officer, Ministry of Health, Labour and Welfare, Japan
Vice-minister for health, and chief medical and global health officer, Ministry of Health, Labour and Welfare, Japan
Sakoi Masami was appointed director-general of the Office for Covid-19 and Other Emerging Infectious Disease Control Cabinet Secretariat in 2021 and appointed to his current position in July 2023. Various roles he has held at the Ministry of Health since 2005 include director, Health Risk Management Office, Minister’s Secretariat; planning director, Health Insurance Bureau; director, Division of Health for the Elderly; director, Medical Care Planning Division; director, Medical Economics Division; deputy director-general of the ministry, Minister’s Secretariat; and director-general of the Health Policy Bureau. Dr Masami also has experience working with the Hiroshima prefectural government as director-general of the Health and Welfare Department (2006–09).
After joining the Ministry of Health and Welfare in 1992, he visited the US to study at the Harvard School of Public Health and received a master of public health in 1997. He graduated from the University of Tokyo Faculty of Medicine in 1989. Dr Masami has served as a surgical clinician at institutions including the University of Tokyo Hospital and Toranomon Hospital.
Group chief health officer, FWD Group
As group chief health officer at FWD Group, Sarah Salvilla leads the company’s business unit that provides comprehensive accident and health insurance. Since assuming this role in 2024, Dr Salvilla is focused on driving innovative partnerships with healthcare providers and industry leaders to deliver customer-led outcomes, utilising the latest developments in health technology and research. She first joined FWD Group in 2021 to lead its group customer and operations team, based in Hong Kong. Prior to joining FWD, Dr Salvilla worked at Bupa from 2011 to 2021 in senior healthcare management roles spanning international markets; she was based in London and Hong Kong.
Dr Salvilla has held various board positions including non-executive director at the Academic Health Science Network in the United Kingdom (2020–23), board director at BEI in Egypt (2018–21) and member of the board of fellows of the Map of Medicine in the United Kingdom (2010–15). Additionally, she served as an external editor for the McGill Journal of Medicine from 2006 to 2007.
Dr Salvilla graduated as a doctor from Imperial College London and began her career as a clinician and surgeon in the United Kingdom’s National Health Service. She later joined the World Health Organisation as a consultant for its safer primary care initiative.
Group chief executive, Zuellig Pharma
John Graham is the group chief executive of Zuellig Pharma, a leading healthcare solutions company dedicated to increasing accessibility in Asia through a full spectrum of world-class distribution, digital and commercial services. Prior to joining Zuellig Pharma, Mr Graham was chief executive of the Invida Group, Singapore; he transformed and executed the sale of the company in 2011 to the Menarini Group. He has also held various global leadership positions in pharmaceutical organisations such as Aventis and Genzyme and has more than 30 years of experience in biotech, pharmaceuticals and healthcare consulting.
Chief executive and managing director, ANDHealth, Australia
Bronwyn Le Grice has over 20 years of executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017 she founded ANDHealth, an organisation that supports digital health companies in Australia by providing education, resources, non-dilutive funding and mentorship to help them navigate the complexities of the healthcare industry.
ANDHealth is now one of Australia’s leading health technology commercialisation organisations with companies participating in its flagship ANDHealth+ programme raising $19.70 in new capital and generating $6.70 in new revenues for every dollar invested. ANDHealth manages over $30m in public and private commitments to digital health commercialisation and provides specialist support to a further $100m of funding managed by Brandon Capital.
Ms Le Grice was a member of the National Health and Medical Research Council for the 2021–24 triennium. She is currently a non-executive director of Lumos Diagnostics, alongside a number of other advisory roles.
Chief executive, Siloam Hospitals, Indonesia
Caroline Riady started her career teaching in public school in Illinois, and taught a few years at Pelita Harapan School in Lippo Village, Indonesia. Later, she served as a lecturer at Pelita Harapan Teachers College. In 2012, she became executive director of Siloam Hospitals Kebon Jeruk. Ms Riady leads Siloam Hospitals networks in more than 30 hospitals and clinics. She was appointed vice-president director in 2016. She obtained a bachelor of arts in primary school education from Wheaton College (US) in 2004.
Provost’s chair professor and director, Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore
Provost’s chair professor and director, Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore
Dean Ho is currently provost’s chair professor and director of the Institute for Digital Medicine (WisDM) at the Yong Loo Lin School of Medicine, director of the N.1 Institute for Health and head of the department of biomedical engineering at the National University of Singapore.
Professor Ho and collaborators manage a portfolio of over ten prospective, interventional human clinical trials. His team successfully developed and validated CURATE.AI, a powerful artificial intelligence platform that personalises human treatment for a broad spectrum of indications ranging from oncology to digital therapeutics and infectious diseases, among others. His team also developed IDentif.AI to optimise combination therapy design against SARS-CoV-2 and to address antimicrobial resistance.
Professor Ho is an elected fellow of the US National Academy of Inventors, the American Association for the Advancement of Science, the American Institute for Medical and Biological Engineering, and the Royal Society of Chemistry. He was also named to the HIMSS Future50 Class of 2021 for his internationally recognised leadership in digital health. He is also a subgroup lead in the World Health Organisation working group for the regulation of AI for health.
Board member, Philippine Alliance of Patient Organisations
Einstein Rojas is a board member of the Philippine Alliance of Patient Organisations. Mr Rojas is also an innovation consultant and an engagement manager of Embiggen Group, based in the US and the Philippines. He is a certified innovation professional by the Global Innovation Management Institute in Cambridge, Massachusetts. He holds a master of science in innovation and business from the Asian Institute of Management and is a recognised innovation coach for college students at the Far Eastern University Institute of Technology Innovation Centre.
Chief executive, American Chamber of Commerce, Singapore, and adjunct associate professor, Saw Swee Hock School of Public Health, National University of Singapore
Chief executive, American Chamber of Commerce, Singapore, and adjunct associate professor, Saw Swee Hock School of Public Health, National University of Singapore
Hsien-Hsien Lei is chief executive of the American Chamber of Commerce (AmCham) in Singapore. Dr Lei is also adjunct associate professor at the National University of Singapore Saw Swee Hock School of Public Health, member of the Johns Hopkins University Bloomberg School of Public Health advisory board, vice-president of the Precision Public Health Asia Society, board member of TalenTtrust, member of the United Women Singapore STEM Advisory Panel and board committee member of SATA CommHealth.
Prior to AmCham, Dr Lei was vice-president, medical and scientific affairs, at Medtronic Asia-Pacific, where she was responsible for the Medtronic Innovation Centres in Japan and Korea, training and education, and the company’s health systems transformation strategy in the region. She has extensive experience in scientific affairs, corporate and healthcare communications, advertising, public relations and government affairs.
Dr Lei has lived and worked in the US, Taiwan, Japan, Vietnam and the UK, and is now based in Singapore. She holds a BA (with honours) in human biology from Stanford University and a PhD in epidemiology from the Johns Hopkins University Bloomberg School of Public Health, where she was the recipient of a cardiovascular disease epidemiology training grant from the US National Institutes of Health. Her doctoral thesis explored the genetic epidemiology of end-stage renal disease and type 2 diabetes. She completed her post-doctoral fellowship at National Taiwan University Hospital in the department of internal medicine.
Group chief digital officer, National University Health System, Singapore
Peter Forbes is group chief digital officer at National University Health System, where he leads digital strategy and transformation. NUHS innovates digital services to provide healthcare powered by automation and AI, which inspires the residents of western Singapore to take ownership of their health. His current work includes the OneNUHS mobile app, population health, CRM, telemedicine, robotic process automation and IT workspace. He has over 20 years of experience working across business, digital and IT functions to deliver value from technology-enabled change. Prior to NUHS Mr Forbes performed consulting roles at Boston Consulting Group and IBM.
Chief technology strategist, MOH Office for Healthcare Transformation, Singapore
Chief technology strategist, MOH Office for Healthcare Transformation, Singapore
Robert JT Morris is chief technology strategist for the Ministry of Health Transformation (MOHT) Singapore and concurrently professor, National University of Singapore Yong Loo Lin School of Medicine. He is also an adviser to the National Research Foundation in the Prime Minister’s Office. His current focus is on application of computer and information sciences, including AI, to transform healthcare.
From 2011 to 2017, Mr Morris led all of IBM Research’s global laboratories, in Australia, Africa, China, India, Japan, Singapore and South America. During 2006–11, he was vice-president of services research at the IBM TJ Watson Research Centre in New York, helping to start IBM’s healthcare and IoT businesses, and earlier vice-president of assets innovation for IBM Global Services. From 1999 to 2004, he was vice-president and director of IBM Almaden Research Centre in Silicon Valley, where innovations such as relational database technology and the disk drive were invented. Earlier he led advanced systems research at TJ Watson Centre, including the Deep Blue chess machine, which defeated world champion Garry Kasparov in 1997. Originally from Australia, Mr Morris began his career at Bell Labs working on early neural networks and the largest packet switch of the era. He has lived in and worked from Asia since 2011.
Case studies and solution-focused
industry tracks
Hear from healthcare stakeholders in business, policy, research, non-profit and more
See which organisations provide their valued support to the event
Gain access to 15+ live sessions featuring 50+ expert speakers and connect with 500 senior health players.
FWD Group is a pan-Asian life insurance business with more than 13 million customers across 10 markets, including some of the fastest-growing insurance markets in the world. The company was established in 2013 and is focused on changing the way people feel about insurance. FWD’s customer-led and digitally enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience.
For more information, please visit www.fwd.com
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.
Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Prudential Assurance Company Singapore (Pte) Ltd is one of the top life insurance companies in Singapore, serving the financial and protection needs of the country’s citizens for 93 years. The company has an AA- Financial Strength Rating from leading credit rating agency Standard & Poor’s, with S$53.3 billion funds under management as at 31 December 2023. It delivers a suite of well-rounded product offerings in Protection, Savings and Investment through multiple distribution channels including a network of more than 5,200 financial representatives.
InterSystems, a creative data technology provider, delivers a unified foundation for next-generation applications for healthcare, finance, manufacturing, and supply chain customers in more than 80 countries. Our cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe to unlock the power of data and allow people to perceive data in imaginative ways. Established in 1978, InterSystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 39 offices in 28 countries worldwide
ACCESS Health International is a non-profit think tank dedicated to improving access to high-quality, affordable healthcare for all. Through research, policy advocacy, and evidence-based action, we work towards policy changes that drive health systems strengthening.
With a systems approach to addressing healthcare challenges, we collaborate closely with governments, healthcare providers, academia, development partners, and other private organizations to drive positive change in the health sector. Our areas of expertise include health systems research, strategy consulting, technical support, implementation support, and capacity building for both public and private stakeholders.
At ACCESS Health International, we believe in channelling innovations to build resilient health systems. Through wide-ranging initiatives, including implementation research, government advisory, and health advocacy, we strive to make a significant difference in the healthcare landscape.
We collaborate with governments at national and regional levels, providing technical advisory and support to improve healthcare services for vulnerable communities. As a 501(c)(3) charity organization, we are dedicated to social impact. We foster strategic partnerships to drive sustainable and inclusive healthcare solutions.
With offices in different regions, including India, Southeast Asia, and the United States, we actively engage in research, capacity building, and convening networks to advance healthcare across various levels.
The EU-ASEAN Business Council (EU-ABC) is the primary voice for European business within the ASEAN region. It is formally recognised by the European Commission and accredited under Annex 2 of the ASEAN Charter as an entity associated with ASEAN.
Independent of both bodies, the Council has been established to help promote the interests of European businesses operating within ASEAN and to advocate for changes in policies and regulations which would help promote trade and investment between Europe and the ASEAN region. As such, the Council works on a sectorial and cross-industry basis to help improve the investment and trading conditions for European businesses in the ASEAN region through influencing policy and decision makers throughout the region and in the EU, as well as acting as a platform for the exchange of information and ideas amongst its members and regional players within the ASEAN region.
IPI is an innovation catalyst that creates opportunities for enterprises to grow beyond boundaries.
As a subsidiary of Enterprise Singapore, IPI accelerates the innovation process of enterprises through access to its global innovation ecosystem and advisory services.
With a strong belief that innovation is key to enterprise growth, IPI provides enterprises with access to innovative ideas and technologies. We also facilitate and support enterprises’ innovation processes, including commercialisation and go-to-market strategies. Find out more here https://www.ipi-singapore.org
iMPACT magazine is a repository of exclusive content for individuals in the development sector, particularly Institutional/Corporate workers, Non-profit Professionals, and Development Sector Students, providing insights on the most recent innovations, best practices, case studies, research, and career guidance to young agents of change in South and Southeast Asia.
For speaking opportunities please contact [email protected]
Please submit the form and we will reach out to you with more information.
Thank you for submitting your details. A member of our team will reach out to you at earliest.
Please submit the form and we will reach out to you with more information.
Thank you for submitting your details. A member of our team will reach out to you at earliest.
Please submit the form and we will reach out to you with more information.
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.
Please submit the form and we will reach out to you with more information.
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.
Complete the form below if you’re interested in attending our Climate Week events:
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.
Please submit the form and we will reach out to you with more information.
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.
Please submit the form and we will reach out to you with more information.
Thank you for showing interest in the event. We will reach out to you with more information on the registration process.